Saturday 17 October 2026
Export TRDA’s income statement to Excel — free account
Entrada Therapeutics, Inc.
TRDA Healthcare Biotechnology
Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024. In the quarter to June 2026, revenue fell 54.0%, EPS grew 2.88% and free cash flow fell 9.10%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.36
0.42
−8.79%
Follow TRDA
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 3 |
P/E ratio |
— | — | — | — | — | 0.00 | 8.69 | 0.00 |
Altman Z-Score |
— | — | — | — | — | 1.53 | 5.23 | 2.15 |
P/S ratio |
— | — | — | — | — | 3.89 | 3.06 | 16.73 |
P/FCF ratio |
— | — | — | — | — | 3.74 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | 2.67 | 9.40 | 4.24 |
P/Operating CF |
— | — | — | — | — | (124.94) | (20.41) | (13.21) |
Beneish M-Score |
— | — | — | — | — | — | (1.32) | (6.07) |
P/B ratio |
— | — | — | — | — | 2.07 | 1.50 | 1.39 |
Price to Tangible BV |
— | — | — | — | — | 2.07 | 1.50 | 1.39 |
EV/Sales |
— | — | — | — | — | 1.16 | 1.07 | 5.07 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 5.52 | 0.00 |
EV/Operating CF |
— | — | — | — | — | 1.07 | (5.41) | (1.00) |
EV/FCF |
— | — | — | — | — | 1.11 | (5.03) | (1.00) |
Quick Ratio |
— | 8.77 | 11.62 | 43.32 | 8.59 | 2.25 | 10.73 | 12.17 |
Current Ratio |
— | 9.08 | 11.89 | 44.46 | 9.55 | 2.33 | 11.15 | 12.53 |
Net Debt/EBITDA |
— | 1.44 | 1.48 | 5.82 | 1.98 | 57.70 | (10.30) | 1.88 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.42 | 0.06 |
Operating CF/Net income |
— | 2.12 | 0.96 | 0.99 | 0.99 | (20.91) | (0.63) | 0.89 |
Capex/Depreciation |
— | (6.06) | (7.11) | (4.10) | (1.41) | 1.91 | 0.51 | (2.45) |
| — | 17.89% | 93.05% | (39.78%) | (37.01%) | (2.94%) | 19.56% | (39.13%) | |
| — | (55.93%) | (85.88%) | (29.29%) | (33.92%) | (1.85%) | 13.18% | (31.81%) | |
ROIC |
— | 0.00% | (1,484.14%) | (417.49%) | (254.93%) | 0.00% | 338.50% | (1,009.37%) |
Return on Tangible Assets |
— | (31.26%) | (66.93%) | (17.15%) | (48.38%) | (3.01%) | 15.95% | (49.72%) |
Average Days of Receivables |
— | — | — | — | — | 16.63 | 6.37 | 16.90 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 77.42% | 59.45% | 559.65% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 25.03% | 18.25% | 161.48% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 10.16% | 8.50% | 77.14% |
Graham Net Nets |
— | — | — | — | — | 0.29 | 0.53 | 0.55 |
Graham Number |
— | — | — | — | — | 0.00 | 22.68 | 0.00 |
Earnings Yield |
— | — | — | — | — | (1.38%) | 11.51% | (33.66%) |
Free Cash Flow Yield |
— | — | — | — | — | 26.76% | (6.93%) | (30.46%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 3.90 | 5.65 | 0.61 |
Operating CF per Share |
— | (11.58) | (23.13) | (8.11) | (3.00) | 4.23 | (1.11) | (3.11) |
Capex per Share |
— | (0.68) | (2.10) | (0.73) | (0.09) | (0.17) | (0.08) | (0.03) |
Free Cash Flow per Share |
— | (12.25) | (25.23) | (8.85) | (3.09) | 4.06 | (1.20) | (3.13) |
Cash per Share |
— | 18.05 | 35.33 | 46.44 | 6.03 | 10.65 | 11.26 | 7.16 |
Shareholders Equity per Share |
— | 17.47 | 36.34 | 47.66 | 6.79 | 7.33 | 11.49 | 7.40 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 17.47 | 36.34 | 47.66 | 6.79 | 7.33 | 11.49 | 7.40 |
Free Cash Flow |
— | (11.43) | (27.89) | (55.44) | (96.67) | 134.19 | (44.71) | (129.55) |
Working Capital |
— | 15.52 | 36.59 | 291.98 | 187.90 | 210.98 | 400.56 | 281.80 |
Capital Expenditures |
— | (0.63) | (2.32) | (4.58) | (2.89) | (5.61) | (3.16) | (1.04) |
Net Current Asset Value |
— | 15.50 | 36.59 | 291.59 | 170.37 | 142.94 | 342.40 | 235.01 |
EV/EBIT |
— | — | — | — | — | 0.00 | 4.79 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 | 0.04 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 13.72 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.13 | 0.11 | 0.18 | 0.27 | (0.26) | (0.57) | 0.06 |
Cash ROIC |
— | (34.49%) | (35.21%) | (9.40%) | (24.09%) | 22.58% | (5.27%) | (21.50%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 44.11 | 10.47 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | — | — | 4.78 | 2.43 |
Average Payables |
— | 1.16 | 1.16 | 1.15 | 3.35 | 4.63 | 3.77 | 3.27 |
Average Assets |
— | 9.12 | 30.88 | 174.68 | 278.94 | 360.62 | 497.76 | 451.85 |
Average Common Equity |
— | (28.50) | (28.50) | 128.61 | 255.64 | 227.46 | 335.52 | 367.41 |
Columns are period end dates